Alzheimer's patients retain the benefits of Leqembi even when they stop the drug, Eisai says [CNBC]
AC Immune SA (ACIU)
Last ac immune sa earnings: 11/13 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
acimmune.com/en/investors
Company Research
Source: CNBC
The Japanese drugmaker and its partner Biogen last week released an additional analysis of clinical trials of the monoclonal antibody drug, which is also known as lecanemab. Alzheimer's disease continued to progress at a slower rate in patients who took Leqembi even when they were off the treatment for an average of two years, the analysis found. The findings come as the drugmakers await a decision on full approval of Leqembi. The Food and Drug Administration approved the treatment on an expedited basis in January, and is slated to make its final decision on July 6. The findings also come as Eisai and Biogen try to regain their footing after the polarizing approval and disastrous rollout of its other Alzheimer's disease therapy, aduhelm, last year. Roughly 6.7 million Americans age 65 and older are living with Alzheimer's, according to the Alzheimer's Association . That group is projected to rise to almost 13 million by 2050. One in three seniors die with Alzheimer's or another
Show less
Read more
Impact Snapshot
Event Time:
ACIU
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ACIU alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ACIU alerts
High impacting AC Immune SA news events
Weekly update
A roundup of the hottest topics
ACIU
News
- AC Immune: Maintaining 'Buy' Rating On Next Steps For ACI-7104.056 Development In PD [Seeking Alpha]Seeking Alpha
- AC Immune posts positive data for Parkinson's immunotherapy [Yahoo! Finance]Yahoo! Finance
- AC Immune Positive Interim Phase 2 Data on ACI-7104.056 Support Potential Slowing of Progression of Parkinson's Disease [Yahoo! Finance]Yahoo! Finance
- AC Immune Positive Interim Phase 2 Data on ACI-7104.056 Support Potential Slowing of Progression of Parkinson’s DiseaseGlobeNewswire
- AC Immune to Present at the Jefferies 2025 London Healthcare ConferenceGlobeNewswire
ACIU
Earnings
- 11/4/25 - Beat
ACIU
Sec Filings
- 12/11/25 - Form 6-K
- 11/4/25 - Form 6-K
- 10/3/25 - Form 144
- ACIU's page on the SEC website